search

Hy7 meeting 2019

Jaarlijks organiseren 7 samenwerkende hypertensie verenigingen uit Europa een Hy7 meeting, dit jaar is deze meeting in Amsterdam op zaterdag 16 november 2019. Een dagvullend programma met ruim 15 presentaties door jonge onderzoekers uit de Hy7 landen en “state of the art lectures” door Thomas Weber, Alexandre Persu, Michel Burnier en Daniel van Raalte.

Interesse om deze meeting bij te wonen? NHV-leden kunnen gratis deelnemen, niet-NHV leden betalen € 60,- per persoon.

Aanmelden kan via: info@nederlandsehypertensievereniging.nl

Scientific organizers:

Organizing secretary: Tanja Verlaan (t.a.verlaan@amsterdamumc.nl)

Location: Vrije Universiteit Medical Centre (VUMC), room ‘de Waver’

PROGRAM HYPERTENSION 7 MEETING, Saturday November 16th, 2019

08:45-09:00 h Welcome Wilko Spiering and Michel Burnier

09:00-10:30 h Session 1. Chair: Eszter Maria Horvath and Gregoire Wuerzner

09:00 h State of the Art 1. Central blood pressure: promises and pitfalls - Thomas Weber, Wels, Austria

09:20 h Prognostic value of ambulatory blood pressure monitoring in patients with CVD - Clarinda Neves, Aveiro, Portugal

09:35 h Association of 24‑hour mean arterial pressure with fatal and nonfatal CVD – time for a paradigm shift? - Jesus Melgarejo, Leuven, Belgium

09:50 h Adherence to hypertension treatment and blood pressure self-monitoring using embedded smartphone camera and advanced image processing - Luis Nogueira-Silva, Oporto, Portugal

10:05 h Correlations between the results of ABPM and the physical condition assessed by cardiac stress tests - Theresa Glantschnig, Graz, Austria

10:20 h Discussion

10:30-11:00 h Coffee break

11:00-12:30 h Session 2. Chair: Bolan Jelakovic and Vitor Paixão Dias

11:00 h State of the Art 2. The European FMD registry: an update - Alexandre Persu, Brussels, Belgium

11:20 h Computational Fluid Dynamics for the identification of hemodynamically significant renal artery stenosis - Lennart van de Velde, Amsterdam, the Netherlands

11:35 h Investigation of diastolic function and its correlation with complications in hypertensive patients - Zoltan Varallyay, Mosonmagyarovar, Hungary

11:50 h Doppler and contrast-enhanced ultrasound responses to a cold pressure test in healthy normotensive participants - Erietta Polychronopoulou, Lausanne, Switzerland

12:05 h Circulating metabolic biomarkers as potential leads for prevention of renal dysfunction - results from a Flemish population study. Zhen-Yu Zhang, Leuven, Belgium

12:20 h Discussion

12:30-14:00 h Lunch

14:00-15:30 h Session 3. Chair: Tine de Backer, Sabine Perl

14:00 h State of the Art 3. Renal effects of glucose lowering therapy - Daniel van Raalte, Amsterdam, the Netherlands

14:20 h Improving CVD risk stratification using biomarkers of arterial stiffness - Mario Podrug, Split, Croatia

14:35 h Evaluation of retinal microvascular dysfunction in patients with cardiovascular risk factors, coronary artery disease and heart failure - Leonie Kreysing, Zurich, Switzerland

14:50 h Clinical implication of assessing quantitative plasma concentrations of antihypertensive drugs - Laura Peeters, Rotterdam, the Netherlands

15:05 h Type 1 diabetes and cardiovascular screening - Simon Helleputte, Ghent, Belgium

15:20 h Discussion

15:30-16:00 h Coffee break

16:00-17:00 h Session 4. Ana Jeroncic, Wilko Spiering

16:00 h State of the Art 4. Novel blood pressure lowering therapies - Michel Burnier, Lausanne, Switzerland

16:20 h Vascular and metabolic effects of vitamin D supplementation in a hyperandrogenic rat model - Krisztina Lajtai, Budapest, Hungary

16:35 h The role of oxidative stress in microvascular endothelial dysfunction induced by high-salt in healthy individuals - Lidija Barić, Osijek, Croatia

16:50 h DNA repair defect in smooth muscle cell (SMC) reproduces features of age-related vascular disease in mice - Keivan Golshiri, Rotterdam, the Netherlands

17:05 h Future collaborations within the Hy7

Chairpersons: Presidents of the Hypertension Societies

17:35 h Wrap up and conclusion

SPONSORS:

Astra Zeneca

Amsterdam Cardiovascular Sciences

Bayer

Boehringer Ingelheim

Microlife

MSD

Novartis

SANOFI